Literature DB >> 28630211

Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition.

Rhian M Touyz1, Ninian N Lang2, Joerg Herrmann2, Anton H van den Meiracker2, A H Jan Danser2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28630211      PMCID： PMC5509510          DOI： 10.1161/HYPERTENSIONAHA.117.08856

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  51 in total

1.  Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.

Authors:  P Carmeliet; Y S Ng; D Nuyens; G Theilmeier; K Brusselmans; I Cornelissen; E Ehler; V V Kakkar; I Stalmans; V Mattot; J C Perriard; M Dewerchin; W Flameng; A Nagy; F Lupu; L Moons; D Collen; P A D'Amore; D T Shima
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 2.  The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Authors:  Langeza Saleh; Koen Verdonk; Willy Visser; Anton H van den Meiracker; A H Jan Danser
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-10

Review 3.  Endothelin-1 and antiangiogenesis.

Authors:  Stephanie Lankhorst; A H Jan Danser; Anton H van den Meiracker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-28       Impact factor: 3.619

4.  Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Authors:  Toni K Choueiri; Erica L Mayer; Youjin Je; Jonathan E Rosenberg; Paul L Nguyen; Georges R Azzi; Joaquim Bellmunt; Harold J Burstein; Fabio A B Schutz
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

5.  An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.

Authors:  Olivier Mir; Romain Coriat; Laure Cabanes; Stanislas Ropert; Bertrand Billemont; Jérôme Alexandre; Jean-Philippe Durand; Jean-Marc Treluyer; Bertrand Knebelmann; François Goldwasser
Journal:  Oncologist       Date:  2011-08-01

6.  Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib.

Authors:  Stephanie Lankhorst; Hans J Baelde; Marian C Clahsen-van Groningen; Frank M M Smedts; A H Jan Danser; Anton H van den Meiracker
Journal:  Nephrol Dial Transplant       Date:  2015-12-17       Impact factor: 5.992

7.  Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

Authors:  Emily S Robinson; Ursula A Matulonis; Percy Ivy; Suzanne T Berlin; Karin Tyburski; Richard T Penson; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

8.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

Authors:  Tammy F Chu; Maria A Rupnick; Risto Kerkela; Susan M Dallabrida; David Zurakowski; Lisa Nguyen; Kathleen Woulfe; Elke Pravda; Flavia Cassiola; Jayesh Desai; Suzanne George; Jeffrey A Morgan; David M Harris; Nesreen S Ismail; Jey-Hsin Chen; Frederick J Schoen; Annick D Van den Abbeele; George D Demetri; Thomas Force; Ming Hui Chen
Journal:  Lancet       Date:  2007-12-15       Impact factor: 79.321

Review 9.  Mechanisms and regulation of endothelial VEGF receptor signalling.

Authors:  Michael Simons; Emma Gordon; Lena Claesson-Welsh
Journal:  Nat Rev Mol Cell Biol       Date:  2016-07-27       Impact factor: 94.444

Review 10.  Antiangiogenic cancer treatment: The great discovery and greater complexity (Review).

Authors:  Ewa Maj; Diana Papiernik; Joanna Wietrzyk
Journal:  Int J Oncol       Date:  2016-09-26       Impact factor: 5.650
View more
  26 in total

Review 1.  Cardiovascular Risk in Cancer Survivors.

Authors:  Inbar Agmon Nardi; Zaza Iakobishvili
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-28

Review 2.  Management of VEGF-Targeted Therapy-Induced Hypertension.

Authors:  Stefano Caletti; Anna Paini; Maria Antonietta Coschignano; Carolina De Ciuceis; Matteo Nardin; Roberto Zulli; Maria Lorenza Muiesan; Massimo Salvetti; Damiano Rizzoni
Journal:  Curr Hypertens Rep       Date:  2018-06-29       Impact factor: 5.369

Review 3.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 4.  Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.

Authors:  Arvind K Pandey; Eric K Singhi; Juan Pablo Arroyo; Talat Alp Ikizler; Edward R Gould; Jonathan Brown; Joshua A Beckman; David G Harrison; Javid Moslehi
Journal:  Hypertension       Date:  2017-12-26       Impact factor: 10.190

Review 5.  Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Authors:  Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

Review 6.  Monitoring haemodynamic changes in rodent models to better inform safety pharmacology: Novel insights from in vivo studies and waveform analysis.

Authors:  Marieke Van Daele; Samantha L Cooper; Patrizia Pannucci; Edward S Wragg; Julie March; Iwan de Jong; Jeanette Woolard
Journal:  JRSM Cardiovasc Dis       Date:  2022-05-23

7.  Research on the Mechanism and Prevention of Hypertension Caused by Apatinib Through the RhoA/ROCK Signaling Pathway in a Mouse Model of Gastric Cancer.

Authors:  Wenjuan Wang; Qingjian He; Caie Li; Chenchen Zhuang; Haodong Zhang; Qiongying Wang; Xin Fan; Miaomiao Qi; Runmin Sun; Jing Yu
Journal:  Front Cardiovasc Med       Date:  2022-06-23

8.  The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice.

Authors:  Zhi-Chao Dong; Ming-Ming Wu; Yun-Long Zhang; Qiu-Shi Wang; Chen Liang; Xiao Yan; Lei-Xin Zou; Chen Chen; Xiao Han; Bo Zhang; Zhi-Ren Zhang
Journal:  Acta Pharmacol Sin       Date:  2020-12-10       Impact factor: 7.169

Review 9.  Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection.

Authors:  Virginia S Hahn; Kathleen W Zhang; Lova Sun; Vivek Narayan; Daniel J Lenihan; Bonnie Ky
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

10.  Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.

Authors:  Syed O Amin; Marcel Ruzicka; Kevin D Burns; Isabelle A Bence-Bruckler; Stephen E Ryan; Adnan Hadziomerovic; Swapnil Hiremath
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-03-16       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.